[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK2787975T3 - Robuste formuleringer med kontrolleret frigivelse - Google Patents

Robuste formuleringer med kontrolleret frigivelse

Info

Publication number
DK2787975T3
DK2787975T3 DK12791490.1T DK12791490T DK2787975T3 DK 2787975 T3 DK2787975 T3 DK 2787975T3 DK 12791490 T DK12791490 T DK 12791490T DK 2787975 T3 DK2787975 T3 DK 2787975T3
Authority
DK
Denmark
Prior art keywords
controlled release
release formulations
robust controlled
robust
formulations
Prior art date
Application number
DK12791490.1T
Other languages
English (en)
Inventor
Fredrik Tiberg
Markus Johnsson
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47226199&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2787975(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Camurus Ab filed Critical Camurus Ab
Application granted granted Critical
Publication of DK2787975T3 publication Critical patent/DK2787975T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
DK12791490.1T 2011-12-05 2012-11-28 Robuste formuleringer med kontrolleret frigivelse DK2787975T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161566851P 2011-12-05 2011-12-05
PCT/EP2012/073843 WO2013083460A1 (en) 2011-12-05 2012-11-28 Robust controlled-release formulations

Publications (1)

Publication Number Publication Date
DK2787975T3 true DK2787975T3 (da) 2017-11-20

Family

ID=47226199

Family Applications (2)

Application Number Title Priority Date Filing Date
DK12791208.7T DK2787974T3 (da) 2011-12-05 2012-11-28 Robuste peptidformuleringer med kontrolleret frigivelse
DK12791490.1T DK2787975T3 (da) 2011-12-05 2012-11-28 Robuste formuleringer med kontrolleret frigivelse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK12791208.7T DK2787974T3 (da) 2011-12-05 2012-11-28 Robuste peptidformuleringer med kontrolleret frigivelse

Country Status (23)

Country Link
US (2) US9585959B2 (da)
EP (2) EP2787975B1 (da)
JP (2) JP6081479B2 (da)
KR (2) KR101979051B1 (da)
CN (2) CN104093399B (da)
AU (2) AU2012348640B2 (da)
BR (2) BR112014013691A2 (da)
CA (2) CA2858227C (da)
CL (1) CL2014001472A1 (da)
CO (1) CO7000746A2 (da)
DK (2) DK2787974T3 (da)
EA (2) EA028040B1 (da)
ES (2) ES2645345T3 (da)
HK (2) HK1201722A1 (da)
HR (1) HRP20170954T1 (da)
IL (2) IL232789B (da)
MX (2) MX352024B (da)
PE (1) PE20141297A1 (da)
PL (1) PL2787975T3 (da)
SG (1) SG11201402673YA (da)
SI (1) SI2787974T1 (da)
WO (2) WO2013083460A1 (da)
ZA (1) ZA201403793B (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005249274B2 (en) * 2004-06-04 2011-02-24 Camurus Ab Liquid depot formulations
GB0711656D0 (en) * 2007-06-15 2007-07-25 Camurus Ab Formulations
PL2714004T3 (pl) * 2011-05-25 2024-08-19 Camurus Ab Preparaty peptydowe o kontrolowanym uwalnianiu
BR112014029425A2 (pt) * 2012-05-25 2017-06-27 Camurus Ab pré-formulação, dispositivo de administração pré-cheio, kit, processo para a formação de uma pré-formulação, usos de mistura e de um solvente polar, e, método para o tratamento de um sujeito
CA2879942C (en) 2012-07-26 2020-06-02 Camurus Ab Opioid formulations
CN109010255B (zh) 2012-07-26 2022-10-21 卡姆拉斯公司 阿片样物质制剂
EP2823808A1 (en) * 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
US10086049B2 (en) 2013-10-22 2018-10-02 Prolynx Llc Conjugates of somatostatin analogues
WO2016092569A1 (en) * 2014-12-10 2016-06-16 Council Of Scientific & Industrial Research A discontinuous reverse micellar composition in cubic fd3m phase for sustained release of therapeutic drugs
AU2015370922B2 (en) * 2014-12-23 2018-10-04 Camurus Ab Controlled-release formulations
GB201516554D0 (en) * 2015-09-18 2015-11-04 Camurus Ab Controlled-release formulations
ITUB20160416A1 (it) * 2016-01-28 2017-07-28 Italfarmaco Spa Uso di una formulazione a lento rilascio di octreotide per la prevenzione della formazione di seroma
RU2018134132A (ru) * 2016-03-31 2020-04-30 Сан Фарма Эдвэнст Рисёрч Кампани Лимитэд Вязкоупругий гель лираглутида, адаптированный для однократного недельного или однократного двухнедельного применения
IL265270B (en) 2016-09-15 2022-09-01 Camurus Ab Prostacyclin analogue formulations
AU2017336199B2 (en) 2016-09-27 2020-08-20 Camurus Ab Mixtures and formulations comprising an alkyl ammonium EDTA salt
US10779576B2 (en) 2017-05-24 2020-09-22 VMR Products, LLC Flavor disk
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
CA3097926A1 (en) * 2018-05-01 2019-11-07 Chibi, Inc. Eye drop formulation and method for sustained delivery of medicament to the retina
AU2019263302C1 (en) 2018-05-01 2024-10-31 Chibi, Inc. Liquid depot for non-invasive sustained delivery of agents to the eye
CN108498849B (zh) * 2018-05-08 2021-04-30 武汉百纳礼康生物制药有限公司 一种液晶凝胶肝动脉栓塞剂及其制备方法
CN109091451B (zh) * 2018-09-10 2021-08-13 武汉百纳礼康生物制药有限公司 亲水性药物的油相液晶凝胶前体制剂及其制备方法
EP3975991A1 (en) 2019-05-29 2022-04-06 Camurus AB Lipid-controlled release compositions
EP4103587A1 (en) 2020-02-14 2022-12-21 Immunor AS Corona virus vaccine
JP7542661B2 (ja) * 2020-06-30 2024-08-30 チョン クン ダン ファーマシューティカル コーポレーション Ｇｎｒｈ誘導体を含む注射用組成物
WO2022093722A1 (en) * 2020-10-27 2022-05-05 Pts Consulting, Llc A liquid injectable composition of donepezil
CN113081954A (zh) * 2021-05-25 2021-07-09 南昌大学第二附属医院 一种凝胶载药贴剂药物输送系统
JPWO2023008498A1 (da) * 2021-07-27 2023-02-02

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8206744D0 (sv) 1982-11-26 1982-11-26 Fluidcarbon International Ab Preparat for kontrollerad avgivning av substanser
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
CA2186750C (en) * 1994-03-30 2008-08-05 Jens Hansen Use of fatty acid esters as bioadhesive substances
SE518578C2 (sv) 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
JP3952617B2 (ja) 1998-12-11 2007-08-01 株式会社日立製作所 内燃機関の排ガス浄化装置，排ガス浄化方法及び排ガス浄化触媒
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US20080112915A1 (en) * 2003-10-24 2008-05-15 Marianna Foldvari Dna Delivery with Gemini Cationic Surfactants
PL1682091T3 (pl) * 2003-11-07 2017-09-29 Camurus Ab Kompozycje lipidów i kationowych peptydów
DE602005025083D1 (da) 2004-01-23 2011-01-13 Camurus Ab
GB0401513D0 (en) 2004-01-23 2004-02-25 Camurus Ab Compositions
AU2005249274B2 (en) 2004-06-04 2011-02-24 Camurus Ab Liquid depot formulations
EP1765367A4 (en) * 2004-06-15 2010-08-11 Therapeutics Inc Encore PHOSPHOLIPID COMPOSITIONS AND METHOD FOR THEIR PREPARATION AND USE
JP5107725B2 (ja) 2005-01-14 2012-12-26 カムルス エービー ＧｎＲＨ類似体製剤
JP5171262B2 (ja) * 2005-01-14 2013-03-27 カムルス エービー ソマトスタチン類似体製剤
CA2595385C (en) 2005-01-21 2011-01-25 Camurus Ab Pharmaceutical lipid compositions
DK1888031T3 (da) 2005-06-06 2013-02-18 Camurus Ab GLP-1-analogformuleringer
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) * 2007-08-22 2007-10-03 Camurus Ab Formulations

Also Published As

Publication number Publication date
PL2787975T3 (pl) 2018-01-31
JP6081480B2 (ja) 2017-02-15
CA2857982A1 (en) 2013-06-13
DK2787974T3 (da) 2017-07-17
IL232789A0 (en) 2014-07-31
EA027924B1 (ru) 2017-09-29
CN104105479A (zh) 2014-10-15
KR20140105527A (ko) 2014-09-01
WO2013083459A1 (en) 2013-06-13
BR112014013693B1 (pt) 2023-01-31
MX2014006624A (es) 2014-09-22
BR112014013691A2 (pt) 2017-06-13
CA2858227C (en) 2021-01-05
ZA201403793B (en) 2017-04-26
SI2787974T1 (sl) 2017-10-30
BR112014013693A2 (pt) 2020-06-30
CA2858227A1 (en) 2013-06-13
HRP20170954T1 (hr) 2017-09-22
US9555118B2 (en) 2017-01-31
WO2013083460A1 (en) 2013-06-13
CO7000746A2 (es) 2014-07-21
CN104093399A (zh) 2014-10-08
EA201490921A1 (ru) 2014-11-28
CL2014001472A1 (es) 2014-11-21
AU2012348641A1 (en) 2014-06-19
EA201491005A1 (ru) 2014-11-28
MX2014006625A (es) 2014-09-22
IL232967A0 (en) 2014-07-31
EP2787975B1 (en) 2017-10-04
KR20140111661A (ko) 2014-09-19
US9585959B2 (en) 2017-03-07
HK1201735A1 (en) 2015-09-11
EP2787974A1 (en) 2014-10-15
EA028040B1 (ru) 2017-09-29
IL232789B (en) 2019-11-28
EP2787975A1 (en) 2014-10-15
JP6081479B2 (ja) 2017-02-15
JP2015505833A (ja) 2015-02-26
ES2629188T3 (es) 2017-08-07
JP2015500253A (ja) 2015-01-05
KR101979051B1 (ko) 2019-05-15
AU2012348641B2 (en) 2016-04-21
PE20141297A1 (es) 2014-10-09
CN104093399B (zh) 2018-03-13
MX352024B (es) 2017-11-07
AU2012348640A1 (en) 2014-07-17
SG11201402673YA (en) 2014-06-27
ES2645345T3 (es) 2017-12-05
CN104105479B (zh) 2018-04-10
AU2012348640B2 (en) 2016-07-21
EP2787974B1 (en) 2017-05-24
HK1201722A1 (en) 2015-09-11
US20140329749A1 (en) 2014-11-06
MX350929B (es) 2017-09-26
US20140348903A1 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
DK2787975T3 (da) Robuste formuleringer med kontrolleret frigivelse
SI3725778T1 (sl) Formulacije enzalutamida
DK3091029T3 (da) Anti-IL13-antistofformuleringer
DK3170508T3 (da) Vaccineformuleringer
DK2714004T3 (da) Peptidformuleringer med kontrolleret frigivelse
SMT201700110B (it) Composizione immunogena
DK3072505T3 (da) Testosteronformuleringer
CO6940426A2 (es) Formulaciones farmacéuticas
EP2755680A4 (en) PARTICULATE VACCINE FORMULATIONS
BR112014005756A2 (pt) vacina
DE112012003251A5 (de) Ausrücksystem
DE112012003262A5 (de) Ausrücksystem
AP3681A (en) Modified release formulations for oprozomib
HRP20181667T1 (hr) Pripravak
IL231660A0 (en) Composition
FR2975564B1 (fr) Charrue
CO6801767A2 (es) Formulaciones de liberación sostenida de paracetamol
DK2672817T3 (da) Forbedrede insekticide formuleringer
DE112012003257A5 (de) Ausrücksystem
DE112012004236A5 (de) Gussstück
CO6960544A2 (es) Preparación de liberación sostenida
GB201210530D0 (en) Extended release formulations
DE112013005394A5 (de) Deckelfester Ausrücker
DE112012003245A5 (de) Ausrücksystem
FR2978106B1 (fr) Voilure amovible